📰 Psytech Ltd News
Psytech Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Psytech Ltd. Real-time updates on events, politics, business and more.
January 4, 2024
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...
December 15, 2023
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
May 4, 2023
BPL-003 is Beckley Psytech's patent-protected benzoate formulation of 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The multi-centre
April 5, 2023
Open-label study will investigate the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD). BPL-003 is Beckley Psytech's patent-protected
February 21, 2023
This is the first time the FDA has given IND approval for a Phase IIb study of a short-acting psychedelic like 5-MeO-DMT (Mebufotenin). Beckley Psytech plans to initiate a global multi-site
February 21, 2023
Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into safe, effective and licensed medicines, today announced that it had received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration ...